Biology and significance of the JAK/STAT signalling pathways

Growth Factors

Volumn 30, Issue 2, 2012, Pages 88-106

  Kiu, Hiu ^a   Nicholson, Sandra E ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cytokine; JAK; receptor; signalling; SOCS; STAT

Indexed keywords

JANUS KINASE; PROTEIN SH2; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

CRYSTAL STRUCTURE; DIMERIZATION; FEEDBACK SYSTEM; GAIN OF FUNCTION MUTATION; HUMAN; IMMUNE RESPONSE; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASES; MICE; MUTATION; MYELOPROLIFERATIVE DISORDERS; PYRAZOLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84858961271     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2012.660936     Document Type: Review

References (309)

1. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T. 1994. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77:63-71.
2. Antunes F, Marg A, Vinkemeier U. 2011. STAT1 signaling is not regulated by a phosphorylation-acetylation switch. Mol Cell Biol 31:3029-3037.
3. Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C. 2004. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol Cell Biol 24:4955-4967. (Pubitemid 38668059)
4. Arora T, Liu B, He H, Kim J, Murphy TL, Murphy KM, Modlin RL, Shuai K. 2003. PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4. J Biol Chem 278:21327-21330. (Pubitemid 36792526)
5. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, Chan TD, Palendira U, Bustamante J, Boisson-Dupuis S, Choo S, Bleasel KE, Peake J, King C, French MA, Engelhard D, Al-Hajjar S, Al-Muhsen S, Magdorf K, Roesler J, Arkwright PD, Hissaria P, Riminton DS, Wong M, Brink R, Fulcher DA, Casanova JL, Cook MC, Tangye SG. 2010. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 207:155-171.
6. Babon JJ, Sabo JK, Zhang JG, Nicola NA, Norton RS. 2009. The SOCS box encodes a hierarchy of affinities for Cullin5: Implications for ubiquitin ligase formation and cytokine signalling suppression. J Mol Biol 387:162-174.
7. Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, Lucet SL, Norton RS, Nicola NA. 2012. SOCS3 binds to a site unique to JAKs and inhibits their kinase activity via a novel, non-competitive mechanism. Immunity, In Press.
8. Banninger G, Reich NC. 2004. STAT2 nuclear trafficking. J Biol Chem 279:39199-39206. (Pubitemid 39258180)
9. Barge RM, de Koning JP, Pouwels K, Dong F, Lowenberg B, Touw IP. 1996. Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route. Blood 87:2148-2153.
10. Bates SH, Stearns WH, Dundon TA, Schubert M, Tso AW, Wang Y, Banks AS, Lavery HJ, Haq AK, Maratos-Flier E, Neel BG, Schwartz MW, Myers MG, Jr. 2003. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 421:856-859. (Pubitemid 36254146)
11. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061. (Pubitemid 40386783)
12. Becker S, Groner B, Muller CW. 1998. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394:145-151. (Pubitemid 28325960)
13. Begitt A, Meyer T, van Rossum M, Vinkemeier U. 2000. Nucleocytoplasmic translocation of Stat1 is regulated by a leucine-rich export signal in the coiled-coil domain. Proc Natl Acad Sci USA 97:10418-10423.
14. Begitt A, Droescher M, Knobeloch KP, Vinkemeier U. 2011. SUMO conjugation of STAT1 protects cells from hyper-responsiveness to IFNgamma. Blood 118:1002-1007.
15. Behrmann I, Smyczek T, Heinrich PC, Schmitz-Van de Leur H, Komyod W, Giese B, Muller-Newen G, Haan S, Haan C. 2004. Janus kinase (Jak) subcellular localization revisited: The exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase. J Biol Chem 279:35486-35493. (Pubitemid 39100548)
16. Bernards A. 1991. Predicted tyk2 protein contains two tandem protein kinase domains. Oncogene 6:1185-1187. (Pubitemid 21924206)
17. Bhattacharya S, Schindler C. 2003. Regulation of Stat3 nuclear export. J Clin Invest 111:553-559. (Pubitemid 36228012)
18. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D'Andrea A, Livingston DM. 1996. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 383:344-347. (Pubitemid 26321765)
19. Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. 1999. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 274:30059-30065.
20. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A, Haugen H, Jelinek L, Kelly JD, Madden K, Maurer MF, Parrish-Novak J, Prunkard D, Sexson S, Sprecher C, Waggie K, West J, Whitmore TE, Yao L, Kuechle MK, Dale BA, Chandrasekher YA. 2001. Interleukin 20: Discovery, receptor identification, and role in epidermal function. Cell 104:9-19. (Pubitemid 32144968)
21. Bode JG, Nimmesgern A, Schmitz J, Schaper F, Schmitt M, Frisch W, Haussinger D, Heinrich PC, Graeve L. 1999. LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6- induced activation of STAT3 in macrophages. FEBS Lett 463: 365-370. (Pubitemid 30001952)
22. Boghaert ER, Sells SF, Walid AJ, Malone P, Williams NM, Weinstein MH, Strange R, Rangnekar VM. 1997. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ 8:881-890. (Pubitemid 27355461)
23. Boulton TG, Zhong Z, Wen Z, Darnell JE, Jr, Stahl N, Yancopoulos GD. 1995. STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase. Proc Natl Acad Sci USA 92:6915-6919.
24. Bousquet C, Susini C, Melmed S. 1999. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest 104:1277-1285. (Pubitemid 29536298)
25. Boyle K, Egan P, Rakar S, Willson TA, Wicks IP, Metcalf D, Hilton DJ, Nicola NA, Alexander WS, Roberts AW, Robb L. 2007. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood 110:1466-1474. (Pubitemid 47443961)
26. Braunstein J, Brutsaert S, Olson R, Schindler C. 2003. STATs dimerize in the absence of phosphorylation. J Biol Chem 278: 34133-34140. (Pubitemid 37553254)
27. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18:2553-2558. (Pubitemid 28183425)
28. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE, Jr. 1999. Stat3 as an oncogene. Cell 98:295-303. (Pubitemid 29380565)
29. Brown S, Zeidler MP. 2008. Unphosphorylated STATs go nuclear. Curr Opin Genet Dev 18:455-460. (Pubitemid 50313604)
30. Cacalano NA, Migone TS, Bazan F, Hanson EP, Chen M, Candotti F, O'Shea JJ, Johnston JA. 1999. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: Mapping of the Jak3-receptor interaction domain. Embo J 18:1549-1558. (Pubitemid 29127068)
31. Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JA, Lammers JW, Koenderman L, de Groot RP. 1996. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem 271:13221-13227. (Pubitemid 26175904)
32. Campbell PJ, Green AR. 2006. The myeloproliferative disorders. N Engl J Med 355:2452-2466. (Pubitemid 44903749)
33. Cance WG, Liu ET. 1995. Protein kinases in human breast cancer. Breast Cancer Res Treat 35:105-114.
34. Chen HC, Reich NC. 2010. Live cell imaging reveals continuous STAT6 nuclear trafficking. J Immunol 185:64-70.
35. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Jr, Kuriyan J. 1998. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93:827-839. (Pubitemid 28257588)
36. Chen Y, Wen R, Yang S, Schuman J, Zhang EE, Yi T, Feng GS, Wang D. 2003. Identification of Shp-2 as a Stat5A phosphatase. J Biol Chem 278:16520-16527. (Pubitemid 36799512)
37. Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM. 2002. Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radio-sensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 1:152-160.
38. Cheon H, Yang J, Stark GR. 2011. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res 31:33-40.
39. Chrencik JE, Patny A, Leung IK, Korniski B, Emmons TL, Hall T, Weinberg RA, Gormley JA, Williams JM, Day JE, Hirsch JL, Kiefer JR, Leone JW, Fischer HD, Sommers CD, Huang HC, Jacobsen EJ, Tenbrink RE, Tomasselli AG, Benson TE. 2010. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 400:413-433.
40. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. 1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803-1805. (Pubitemid 27527648)
41. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Forster I, Clausen BE, Nicola NA, Metcalf D, Hilton DJ, Roberts AW, Alexander WS. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4:540-545. (Pubitemid 36701336)
42. Croker BA, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L, Cluse LA, Sutherland KD, Hartley L, Williams E, Zhang JG, Hilton DJ, Nicola NA, Alexander WS, Roberts AW. 2004. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20:153-165. (Pubitemid 38258392)
43. Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX, Robinson GW, Hennighausen L. 2004. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 24:8037-8047. (Pubitemid 39167454)
44. Dai R, Phillips RA, Karpuzoglu E, Khan D, Ahmed SA. 2009. Estrogen regulates transcription factors STAT-1 and NF-kappaB to promote inducible nitric oxide synthase and inflammatory responses. J Immunol 183:6998-7005.
45. Damen JE, Wakao H, Miyajima A, Krosl J, Humphries RK, Cutler RL, Krystal G. 1995. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. Embo J 14:5557-5568.
46. Darnell JE, Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421. (Pubitemid 24217131)
47. David M, Chen HE, Goelz S, Larner AC, Neel BG. 1995. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 15:7050-7058. (Pubitemid 3004334)
48. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR, Kouzarides T. 2009. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461: 819-822.
49. de Koning JP, Dong F, Smith L, Schelen AM, Barge RM, van der Plas DC, Hoefsloot LH, Lowenberg B, Touw IP. 1996. The membrane-distal cytoplasmic region of human granulocyte colony-stimulating factor receptor is required for STAT3 but not STAT1 homodimer formation. Blood 87:1335-1342.
50. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, Uddin S, Rahman A, Fish EN, Platanias LC. 2003. Activation of protein kinase C delta by IFN-gamma. J Immunol 171:267-273. (Pubitemid 36745297)
51. Decker T, Kovarik P. 2000. Serine phosphorylation of STATs. Oncogene 19:2628-2637. (Pubitemid 30339219)
52. Dittrich E, Haft CR, Muys L, Heinrich PC, Graeve L. 1996. A dileucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J Biol Chem 271:5487-5494.
53. Dong F, van Paassen M, van Buitenen C, Hoefsloot LH, Lowenberg B, Touw IP. 1995. A point mutation in the granulocyte colony-stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the overexpression of a novel G-CSF-R isoform. Blood 85:902-911.
54. Droescher M, Begitt A, Marg A, Zacharias M, Vinkemeier U. 2011. Cytokine-induced paracrystals prolong the activity of signal transducers and activators of transcription (STAT) and provide a model for the regulation of protein solubility by small ubiquitin-like modifier (SUMO). J Biol Chem 286:18731-18746.
55. Durbin JE, Hackenmiller R, Simon MC, Levy DE. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84:443-450. (Pubitemid 26058569)
56. Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, Nabholz M, Bucher P. 2001. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 276:6675-6688.
57. "Janus" Encyclopedia Brittanica Inc. Vol XV, Section 155, 11th Ed.
58. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-924. (Pubitemid 27289595)
59. Fagerlund R, Melen K, Kinnunen L, Julkunen I. 2002. Arginine/ lysine-rich nuclear localization signals mediate interactions between dimeric STATs and importin alpha 5. J Biol Chem 277:30072-30078.
60. Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MG, Jr. 2004. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 24:4968-4978. (Pubitemid 38668060)
61. Feldman GM, Rosenthal LA, Liu X, Hayes MP, Wynshaw-Boris A, Leonard WJ, Hennighausen L, Finbloom DS. 1997. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 90:1768-1776. (Pubitemid 27377286)
62. Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, Schreiber RD, Sheehan K, Hilton DJ, Alexander WS, Hertzog PJ. 2006. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 7:33-39. (Pubitemid 41823866)
63. Ferbeyre G, Moriggl R. 2011. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta 1815:104-114.
64. Firmbach-Kraft I, ByersM, Shows T, Dalla-Favera R, Krolewski JJ. 1990. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5:1329-1336.
65. Frank DA, Mahajan S, Ritz J. 1997. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 100:3140-3148. (Pubitemid 28022852)
66. Fu XY, Kessler DS, Veals SA, Levy DE, Darnell JE, Jr. 1990. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci USA 87:8555-8559.
67. Fu XY, Schindler C, Improta T, Aebersold R, Darnell JE, Jr. 1992. The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci USA 89:7840-7843.
68. Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T. 2010. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem 285:5296-5307.
69. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. 2003. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101:2784-2788. (Pubitemid 36857644)
70. Gao Q, Wolfgang MJ, Neschen S, Morino K, Horvath TL, Shulman GI, Fu XY. 2004. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci USA 101:4661-4666. (Pubitemid 38437467)
71. Gerhartz C, Heesel B, Sasse J, Hemmann U, Landgraf C, Schneider-Mergener J, Horn F, Heinrich PC, Graeve L. 1996. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J Biol Chem 271:12991-12998.
72. Giese B, Au-Yeung CK, Herrmann A, Diefenbach S, Haan C, Kuster A, Wortmann SB, Roderburg C, Heinrich PC, Behrmann I, Muller-Newen G. 2003. Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. J Biol Chem 278:39205-39213. (Pubitemid 37221824)
73. Girault JA, Labesse G, Mornon JP, Callebaut I. 1998. Janus kinases and focal adhesion kinases play in the 4.1 band: A superfamily of band 4.1 domains important for cell structure and signal transduction. Mol Med 4:751-769. (Pubitemid 29180123)
74. Girodon F, Steinkamp MP, Cleyrat C, Hermouet S, Wilson BS. 2011. Confocal imaging studies cast doubt on nuclear localization of JAK2V617F. Blood 118:2633-2634.
75. Gobert S, Chretien S, Gouilleux F, Muller O, Pallard C, Dusanter- Fourt I, Groner B, Lacombe C, Gisselbrecht S, Mayeux P. 1996. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. Embo J 15:2434-2441. (Pubitemid 26151183)
76. Goh KC, Haque SJ, Williams BR. 1999. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. Embo J 18:5601-5608. (Pubitemid 29486379)
77. Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, Adams TE, Davey HW, Nicola NA, Hilton DJ, Alexander WS. 2002. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 16:1394-1406. (Pubitemid 34621085)
78. Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, Willson TA, Zervoudakis P, Metcalf D, Street I, Nicola NA, Nash AD, Fabri LJ, Norstedt G, Ohlsson C, Flores-Morales A, Alexander WS, Hilton DJ. 2005. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115:397-406. (Pubitemid 40385481)
79. Greenlund AC, Farrar MA, Viviano BL, Schreiber RD. 1994. Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). Embo J 13:1591-1600.
80. Griffiths DS, Li J, Dawson MA, Trotter MW, Cheng YH, Smith AM, Mansfield W, Liu P, Kouzarides T, Nichols J, Bannister AJ, Green AR, Gottgens B. 2011. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol 13:13-21.
81. Gurniak CB, Berg LJ. 1996. Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood 87:3151-3160. (Pubitemid 26115343)
82. Haan C, Is'harc H, Hermanns HM, Schmitz-Van De Leur H, Kerr IM, Heinrich PC, Grotzinger J, Behrmann I. 2001. Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. J Biol Chem 276:37451-37458.
83. Haan S, Margue C, Engrand A, Rolvering C, Schmitz-Van de Leur H, Heinrich PC, Behrmann I, Haan C. 2008. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol 180:998-1007.
84. Haan C, Behrmann I, Haan S. 2010. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med 14:504-527.
85. Hahm B, Trifilo MJ, Zuniga EI, Oldstone MB. 2005. Viruses evade the immune system through type I interferon-mediated STAT2- dependent, but STAT1-independent, signaling. Immunity 22:247-257. (Pubitemid 40255715)
86. Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF. 1992. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7:1347-1353.
87. Haspel RL, Salditt-Georgieff M, Darnell JE, Jr. 1996. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. Embo J 15:6262-6268. (Pubitemid 26397899)
88. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM. 2003. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100:14133-14138. (Pubitemid 37499203)
89. Heim MH, Kerr IM, Stark GR, Darnell JE, Jr. 1995. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 267:1347-1349.
90. Hendry L, John S. 2004. Regulation of STAT signalling by proteolytic processing. Eur J Biochem 271:4613-4620. (Pubitemid 40065564)
91. Herrada G, Wolgemuth DJ. 1997. The mouse transcription factor Stat4 is expressed in haploid male germ cells and is present in the perinuclear theca of spermatozoa. J Cell Sci 110(Pt 14):1543-1553. (Pubitemid 27338742)
92. Hilfiker-Kleiner D, Hilfiker A, Drexler H. 2005. Many good reasons to have STAT3 in the heart. Pharmacol Ther 107:131-137. (Pubitemid 40800411)
93. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D, Nicola NA. 1998. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95:114-119. (Pubitemid 28103916)
94. Hoey T, Zhang S, Schmidt N, Yu Q, Ramchandani S, Xu X, Naeger LK, Sun YL, Kaplan MH. 2003. Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses. Embo J 22:4237-4248. (Pubitemid 37021751)
95. Hokuto I, Ikegami M, Yoshida M, Takeda K, Akira S, Perl AK, Hull WM, Wert SE, Whitsett JA. 2004. Stat-3 is required for pulmonary homeostasis during hyperoxia. J Clin Invest 113:28-37. (Pubitemid 38541629)
96. Hombria JC, Brown S. 2002. The fertile field of Drosophila Jak/STAT signalling. Curr Biol 12:R569-R575. (Pubitemid 34915536)
97. Horvath CM, Wen Z, Darnell JE, Jr. 1995. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 9:984-994.
98. Hou J, SchindlerU, Henzel WJ, Ho TC, Brasseur M, McKnight SL. 1994. An interleukin-4-induced transcription factor: IL-4 Stat. Science 265:1701-1706.
99. Hou SX, Zheng Z, Chen X, Perrimon N. 2002. The Jak/STAT pathway in model organisms: Emerging roles in cell movement. Dev Cell 3:765-778. (Pubitemid 35460778)
100. Huang LJ, Constantinescu SN, Lodish HF. 2001. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 8:1327-1338. (Pubitemid 34085003)
101. Hunter MG, Avalos BR. 1999. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood 93:440-446. (Pubitemid 29035725)
102. Ihle JN. 1996. STATs: Signal transducers and activators of transcription. Cell 84:331-334. (Pubitemid 26058558)
103. Ilaria RL, Jr, Hawley RG, Van Etten RA. 1999. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93:4154-4166. (Pubitemid 29279258)
104. Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB, Davey HW, Leonard WJ. 1998. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 188:2067-2074. (Pubitemid 28562523)
105. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G, Griffiths E, Krawczyk C, Richardson CD, Aitken K, Iscove N, Koretzky G, Johnson P, Liu P, Rothstein DM, Penninger JM. 2001. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409:349-354. (Pubitemid 32151240)
106. Ishida-Takahashi R, Rosario F, Gong Y, Kopp K, Stancheva Z, Chen X, Feener EP, Myers MG, Jr. 2006. Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling. Mol Cell Biol 26:4063-4073. (Pubitemid 43788010)
107. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148. (Pubitemid 40663494)
108. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. 2010. JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: Approaches for targeted therapies. Genes Cancer 1:979-993.
109. Jerke U, Tkachuk S, Kiyan J, Stepanova V, Kusch A, Hinz M, Dietz R, Haller H, Fuhrman B, Dumler I. 2009. Stat1 nuclear translocation by nucleolin upon monocyte differentiation. PLoS One 4:e8302.
110. John J, McKendry R, Pellegrini S, Flavell D, Kerr IM, Stark GR. 1991. Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol Cell Biol 11:4189-4195. (Pubitemid 21895809)
111. Kampa D, Burnside J. 2000. Computational and functional analysis of the putative SH2 domain in Janus kinases. Biochem Biophys Res Commun 278:175-182.
112. Kamura T, Sato S, Haque D, Liu L, Kaelin WG, Jr, Conaway RC, Conaway JW. 1998. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 12:3872-3881. (Pubitemid 29024849)
113. Kaplan MH, Sun YL, Hoey T, Grusby MJ. 1996. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4- deficient mice. Nature 382:174-177. (Pubitemid 26242885)
114. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G, Pfeffer K, Muller M. 2000. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13:549-560.
115. Kawamura M, McVicar DW, Johnston JA, Blake TB, Chen YQ, Lal BK, Lloyd AR, Kelvin DJ, Staples JE, Ortaldo JR, et al. 1994. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci USA 91:6374-6378. (Pubitemid 24200663)
116. Kawashima T, Bao YC, Nomura Y, Moon Y, Tonozuka Y, Minoshima Y, Hatori T, Tsuchiya A, Kiyono M, Nosaka T, Nakajima H, Williams DA, Kitamura T. 2006. Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. J Cell Biol 175:937-946. (Pubitemid 44969199)
117. Kawashima T, Bao YC, Minoshima Y, Nomura Y, Hatori T, Hori T, Fukagawa T, Fukada T, Takahashi N, Nosaka T, Inoue M, Sato T, Kukimoto-Niino M, Shirouzu M, Yokoyama S, Kitamura T. 2009. A Rac GTPase-activating protein, MgcRacGAP, is a nuclear localizing signal-containing nuclear chaperone in the activation of STAT transcription factors. Mol Cell Biol 29:1796-1813.
118. Kessler DS, Veals SA, Fu XY, Levy DE. 1990. Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev 4: 1753-1765.
119. Kieslinger M, Woldman I, Moriggl R, Hofmann J, Marine JC, Ihle JN, Beug H, Decker T. 2000. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev 14:232-244. (Pubitemid 30070988)
120. Kimura A, Kinjyo I, Matsumura Y, Mori H, Mashima R, Harada M, Chien KR, Yasukawa H, Yoshimura A. 2004. SOCS3 is a physiological negative regulator for granulopoiesis and granulocyte colony-stimulating factor receptor signaling. J Biol Chem 279:6905-6910. (Pubitemid 38248833)
121. Kindwall-Keller TL, Druhan LJ, Ai J, Hunter MG, Massullo P, Loveland M, Avalos BR. 2008. Role of the proteasome in modulating native G-CSFR expression. Cytokine 43:114-123.
122. Kiu H, Hilton DJ, Nicola NA, Ernst M, Marquez R, Alexander WS, Roberts AW, McManus EJ. 2007. Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNFalpha. Growth Factors 25:319-328. (Pubitemid 351194030)
123. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. 1995. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729-738.
124. Kohler M, Ansieau S, Prehn S, Leutz A, Haller H, Hartmann E. 1997. Cloning of two novel human importin-alpha subunits and analysis of the expression pattern of the importin-alpha protein family. FEBS Lett 417:104-108. (Pubitemid 27490483)
125. Kohlhuber F, Rogers NC, Watling D, Feng J, Guschin D, Briscoe J, Witthuhn BA, Kotenko SV, Pestka S, Stark GR, Ihle JN, Kerr IM. 1997. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol 17:695-706. (Pubitemid 27044369)
126. Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM, Mullen TM, Glass CK, Rosenfeld MG. 1998. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279:703-707. (Pubitemid 28144549)
127. Kotaja N, Vihinen M, Palvimo JJ, Janne OA. 2002. Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling. J Biol Chem 277:17781-17788. (Pubitemid 34967585)
128. Kovarik P, Stoiber D, Novy M, Decker T. 1998. Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation. Embo J 17:3660-3668. (Pubitemid 28327384)
129. Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M, Cohen P, Decker T. 1999. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. Proc Natl Acad Sci USA 96:13956-13961.
130. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790. (Pubitemid 40570926)
131. Kramer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, Guhrs KH, Stauber RH, Bohmer FD, Heinzel T. 2009. A phosphorylation- acetylation switch regulates STAT1 signaling. Genes Dev 23:223-235.
132. Krishnan K, Singh B, Krolewski JJ. 1998. Identification of amino acid residues critical for the Src-homology 2 domain-dependent docking of Stat2 to the interferon alpha receptor. J Biol Chem 273:19495-19501. (Pubitemid 28367000)
133. Lackmann M, Harpur AG, Oates AC, Mann RJ, Gabriel A, Meutermans W, Alewood PF, Kerr IM, Stark GR, Wilks AF. 1998. Biomolecular interaction analysis of IFN gamma-induced signaling events in whole-cell lysates: Prevalence of latent STAT1 in high-molecular weight complexes. Growth Factors 16:39-51. (Pubitemid 28499710)
134. Landsman T, Waxman DJ. 2005. Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization. J Biol Chem 280:37471-37480. (Pubitemid 41642355)
135. Lebrun JJ, Ali S, Ullrich A, Kelly PA. 1995. Proline-rich sequence-mediated Jak2 association to the prolactin receptor is required but not sufficient for signal transduction. J Biol Chem 270:10664-10670.
136. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397. (Pubitemid 40544655)
137. Levy DE, Darnell JE, Jr. 2002. Stats: Transcriptional control and
138. Levy DE, Kessler DS, Pine R, Reich N, Darnell JE, Jr. 1988. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev 2:383-393.
139. Levy DE, Kessler DS, Pine R, Darnell JE, Jr. 1989. Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro. Genes Dev 3:1362-1371.
140. Li S, Chen S, Xu X, Sundstedt A, Paulsson KM, Anderson P, Karlsson S, Sjogren HO, Wang P. 2000. Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med 191:985-994.
141. Li N, Grivennikov SI, Karin M. 2011. The unholy trinity: Inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19:429-431.
142. Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, et al. 1995. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2:331-339.
143. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. 1995. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 92:8831-8835.
144. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. 1997. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11:179-186. (Pubitemid 27081895)
145. Liu B, Liao J, Rao X, Kushner SA, ChungCD, ChangDD, Shuai K. 1998. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci USA 95:10626-10631. (Pubitemid 28413118)
146. Liu B, Gross M, ten Hoeve J, Shuai K. 2001. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. Proc Natl Acad Sci USA 98:3203-3207. (Pubitemid 32220823)
147. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY, Chang CS. 2003. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 123:654-661.
148. Liu B, Mink S, Wong KA, Stein N, Getman C, Dempsey PW, Wu H, Shuai K. 2004. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 5:891-898. (Pubitemid 39276233)
149. Liu L, McBride KM, Reich NC. 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci USA 102:8150-8155. (Pubitemid 40800058)
150. Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O, Harr MW, Levine RL, Xu H, Tefferi A, Deblasio A, Hatlen M, Menendez S, Nimer SD. 2011. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 19:283-294.
151. Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, Walter M, Burns CJ, Treutlein H, Wilks AF, Rossjohn J. 2006. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107:176-183. (Pubitemid 43053540)
152. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ, et al. 1995. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377:65-68.
153. Mao X, Ren Z, Parker GN, Sondermann H, Pastorello MA, Wang W, McMurray JS, Demeler B, Darnell JE, Jr, Chen X. 2005. Structural bases of unphosphorylated STAT1 association and receptor binding. Mol Cell 17:761-771. (Pubitemid 40386938)
154. Marg A, Shan Y, Meyer T, Meissner T, Brandenburg M, Vinkemeier U. 2004. Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1. J Cell Biol 165:823-833. (Pubitemid 38821973)
155. Marine JC, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimura A, Ihle JN. 1999. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98:617-627. (Pubitemid 29418953)
156. Martinez-Moczygemba M, Huston DP, Lei JT. 2007. JAK kinases control IL-5 receptor ubiquitination, degradation, and internalization. J Leukoc Biol 81:1137-1148. (Pubitemid 46495663)
157. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. 1997. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89:3148-3154.
158. Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, Hayashi I, Tsuji K, Nakahata T, Okabe M, Yamada S, Yoshimura A. 1999. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 19:6396-6407. (Pubitemid 29399343)
159. Matthews DJ, Clark PA, Herbert J, Morgan G, Armitage RJ, Kinnon C, Minty A, Grabstein KH, Caput D, Ferrara P, et al. 1995. Function of the interleukin-2 (IL-2) receptor gammachain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15. Blood 85:38-42.
160. McBride KM, McDonald C, Reich NC. 2000. Nuclear export signal located within theDNA-binding domain of the STAT1- transcription factor. Embo J 19:6196-6206.
161. McKendry R, Pellegrini S, Kerr IM, Stark GR. 1994. Constitutive production of alpha and beta interferons in mutant human cell lines. J Virol 68:4057-4062. (Pubitemid 24177437)
162. Melen K, Kinnunen L, Julkunen I. 2001. Arginine/lysine-rich structural element is involved in interferon-induced nuclear import of STATs. J Biol Chem 276:16447-16455.
163. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver- Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431-442. (Pubitemid 26058568)
164. Mertens C, Zhong M, Krishnaraj R, ZouW, Chen X, Darnell JE, Jr. 2006. Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes Dev 20: 3372-3381. (Pubitemid 44969156)
165. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ, Alexander WS. 2000. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069-1073. (Pubitemid 30447793)
166. Meyer T, Vinkemeier U. 2004. Nucleocytoplasmic shuttling of STAT transcription factors. Eur J Biochem 271:4606-4612. (Pubitemid 40065563)
167. Meyer T, Marg A, Lemke P, Wiesner B, Vinkemeier U. 2003. DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1. Genes Dev 17:1992-2005. (Pubitemid 36999326)
168. Meyer T, Hendry L, Begitt A, John S, Vinkemeier U. 2004. A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors. J Biol Chem 279:18998-19007. (Pubitemid 38623330)
169. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, Takada H, Hara T, Kawamura N, Ariga T, Kaneko H, Kondo N, Tsuge I, Yachie A, Sakiyama Y, Iwata T, Bessho F, Ohishi T, Joh K, Imai K, Kogawa K, Shinohara M, Fujieda M, Wakiguchi H, Pasic S, Abinlun M, Ochs HD, Renner ED, Jansson A, Belohradsky BH, Metin A, Shimizu N, Mizutani S, Miyawaki T, Nonoyama S, Karasuyama H. 2006. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:745-755. (Pubitemid 46131400)
170. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer A, van Deursen J, Sangster MY, Bunting KD, Grosveld GC, Ihle JN. 1999a. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10: 249-259. (Pubitemid 29115630)
171. Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN. 1999b. Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity 11:225-230. (Pubitemid 29428815)
172. Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, Gingras S, Hoffmeyer A, Bauer A, Piekorz R, Wang D, Bunting KD, Wagner EF, Sonneck K, Valent P, Ihle JN, Beug H. 2005. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell 7:87-99. (Pubitemid 40126385)
173. Mowen K, David M. 2000. Regulation of STAT1 nuclear export by Jak1. Mol Cell Biol 20:7273-7281.
174. Mui AL, Wakao H, Harada N, O'Farrell AM, Miyajima A. 1995. Interleukin-3, granulocyte-macrophage colony-stimulating factor, and interleukin-5 transduce signals through two forms of STAT5. J Leukoc Biol 57:799-803.
175. Muller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Silvennoinen O, Harpur AG, Barbieri G, Witthuhn BA, Schindler C, et al. 1993a. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366:129-135. (Pubitemid 23351817)
176. Muller M, Laxton C, Briscoe J, Schindler C, Improta T, Darnell JE, Jr, Stark GR, Kerr IM. 1993b. Complementation of a mutant cell line: Central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. Embo J 12:4221-4228. (Pubitemid 23302036)
177. Musso T, Johnston JA, Linnekin D, Varesio L, Rowe TK, O'Shea JJ, McVicar DW. 1995. Regulation of JAK3 expression in human monocytes: Phosphorylation in response to interleukins 2, 4, and 7. J Exp Med 181:1425-1431.
178. Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, Salmeen A, Barford D, Tonks NK. 2001. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 276:47771-47774.
179. Naeger LK, McKinney J, Salvekar A, Hoey T. 1999. Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling. J Biol Chem 274:1875-1878.
180. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hibi M, Hirano T. 1996. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. Embo J 15:3651-3658. (Pubitemid 26239777)
181. Ndubuisi MI, Guo GG, Fried VA, Etlinger JD, Sehgal PB. 1999. Cellular physiology of STAT3: Where's the cytoplasmic monomer? J Biol Chem 274:25499-25509.
182. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. 1998. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93:397-409. (Pubitemid 28232084)
183. Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS, Metcalf D, Hilton DJ, Nicola NA. 1999. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. Embo J 18:375-385. (Pubitemid 29041946)
184. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Metcalf D, Hilton DJ, Nicola NA, Baca M. 2000. Suppressor of cytokine signaling- 3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97:6493-6498. (Pubitemid 30412741)
185. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN. 1995. Defective lymphoid development in mice lacking Jak3. Science 270:800-802.
186. Okada S, Nakamura M, Katoh H, Miyao T, Shimazaki T, Ishii K, Yamane J, Yoshimura A, Iwamoto Y, Toyama Y, Okano H. 2006. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med 12:829-834. (Pubitemid 44050074)
187. Onischenko E, Weis K. 2011. Nuclear pore complex-a coat specifically tailored for the nuclear envelope. Curr Opin Cell Biol 23:293-301.
188. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M, Miyajima A, Kitamura T. 1998. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 18:3871-3879. (Pubitemid 28287910)
189. Ota N, Brett TJ, Murphy TL, Fremont DH, Murphy KM. 2004. N-domain-dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation. Nat Immunol 5:208-215. (Pubitemid 38208363)
190. Owaki T, Asakawa M, Morishima N, Mizoguchi I, Fukai F, Takeda K, Mizuguchi J, Yoshimoto T. 2008. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J Immunol 180:2903-2911.
191. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A. 2011. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29:789-796.
192. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. 1998. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385-395. (Pubitemid 28232083)
193. Park C, Li S, Cha E, Schindler C. 2000. Immune response in Stat2 knockout mice. Immunity 13:795-804. (Pubitemid 32041802)
194. Paulson M, Pisharody S, Pan L, Guadagno S, Mui AL, Levy DE. 1999. Stat protein transactivation domains recruit p300/CBP through widely divergent sequences. J Biol Chem 274:25343-25349.
195. Pearson MA, Reczek D, Bretscher A, Karplus PA. 2000. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 101:259-270.
196. Pellegrini S, John J, Shearer M, Kerr IM, Stark GR. 1989. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol 9:4605-4612. (Pubitemid 19275926)
197. Perry ST, Buck MD, Lada SM, Schindler C, Shresta S. 2011. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog 7:e1001297.
198. Pezet A, Favre H, Kelly PA, Edery M. 1999. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J Biol Chem 274:24497-24502.
199. Putoczki T, Ernst M. 2010. More than a sidekick: The IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 88:1109-1117.
200. Qing Y, Costa-Pereira AP, Watling D, Stark GR. 2005. Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS- 1-mediated attenuation of STAT1 activation. J Biol Chem 280:1849-1853.
201. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. 2011. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10:127-140.
202. Radtke S, Haan S, Jorissen A, Hermanns HM, Diefenbach S, Smyczek T, Schmitz-Vandeleur H, Heinrich PC, Behrmann I, Haan C. 2005. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem 280:25760-25768. (Pubitemid 40962286)
203. Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S. 2003. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. Embo J 22:537-547. (Pubitemid 36193598)
204. Ram PA, Waxman DJ. 1999. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 274:35553-35561. (Pubitemid 129512851)
205. Ram PA, Waxman DJ. 2000. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J Biol Chem 275:39487-39496. (Pubitemid 32058975)
206. Rane SG, Reddy EP. 1994. JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 9:2415-2423. (Pubitemid 24228695)
207. Rhee SH, Jones BW, Toshchakov V, Vogel SN, Fenton MJ. 2003. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J Biol Chem 278:22506-22512. (Pubitemid 36830305)
208. Richter MF, Dumenil G, Uze G, Fellous M, Pellegrini S. 1998. Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1. J Biol Chem 273:24723-24729. (Pubitemid 28454973)
209. Roberts AW, Robb L, Rakar S, Hartley L, Cluse L, Nicola NA, Metcalf D, Hilton DJ, Alexander WA. 2001. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signalling (SOCS)-3. PNAS 98:9324-9329. (Pubitemid 32743915)
210. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM, Jr, Schreiber RD. 1998. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93:373-383. (Pubitemid 28232082)
211. Rogers RS, Horvath CM, Matunis MJ. 2003. SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation. J Biol Chem 278:30091-30097. (Pubitemid 36962401)
212. Roth W, Sustmann C, Kieslinger M, Gilmozzi A, Irmer D, Kremmer E, Turck C, Grosschedl R. 2004. PIASy-deficient mice display modest defects in IFN and Wnt signaling. J Immunol 173:6189-6199. (Pubitemid 39487776)
213. Russell SM, Johnston JA, Noguchi M, Kawamura M, Bacon CM, Friedmann M, Berg M, McVicar DW, Witthuhn BA, Silvennoinen O, et al. 1994. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: Implications for XSCID and XCID. Science 266:1042-1045.
214. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O'Shea JJ, Leonard WJ. 1995. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 270:797-800.
215. Saharinen P, Silvennoinen O. 2002. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277:47954-47963. (Pubitemid 36159324)
216. Saharinen P, Takaluoma K, Silvennoinen O. 2000. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 20:3387-3395. (Pubitemid 30243884)
217. Saharinen P, Vihinen M, Silvennoinen O. 2003. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14:1448-1459. (Pubitemid 36547413)
218. Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, Yoshikawa K, Akira S, Takeda J. 1999. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. Embo J 18:4657-4668. (Pubitemid 29415520)
219. Santos CI, Costa-Pereira AP. 2011. Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta 1816:38-49.
220. Santti H, Mikkonen L, Anand A, Hirvonen-Santti S, Toppari J, Panhuysen M, Vauti F, Perera M, Corte G, Wurst W, Janne OA, Palvimo JJ. 2005. Disruption of the murine PIASx gene results in reduced testis weight. J Mol Endocrinol 34:645-654. (Pubitemid 40903590)
221. Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O. 2011. Analysis of Jak2 catalytic function by peptide microarrays: The role of the JH2 domain and V617F mutation. PLoS One 6:e18522.
222. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A. 1999. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4:339-351. (Pubitemid 29359449)
223. Schindler C, Darnell JE, Jr. 1995. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway. Annu Rev Biochem 64:621-651.
224. Schindler C, Fu XY, Improta T, Aebersold R, Darnell JE, Jr. 1992a. Proteins of transcription factor ISGF-3: One gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA 89:7836-7839.
225. Schindler C, Shuai K, Prezioso VR, Darnell JE, Jr. 1992b. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257:809-813.
226. Schmidt D, Muller S. 2003. PIAS/SUMO: New partners in transcriptional regulation. Cell Mol Life Sci 60:2561-2574. (Pubitemid 38041360)
227. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Van Rompaey L, Van Etten RA, Ilaria R, Jr, Marynen P, Gilliland DG. 1998. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. Embo J 17: 5321-5333. (Pubitemid 28427047)
228. Sekimoto T, Imamoto N, Nakajima K, Hirano T, Yoneda Y. 1997. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. Embo J 16:7067-7077. (Pubitemid 27520806)
229. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA, Doherty PC, Grosveld G, Paul WE, Ihle JN. 1996. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380:630-633. (Pubitemid 26119016)
230. Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M, Yamashita M, Numata A, Takase K, Kobayashi S, Shibata S, Asano Y, Gondo H, Sekiguchi K, Nakayama K, Nakayama T, Okamura T, Okamura S, Niho Y. 2000. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12- mediated T cell function. Immunity 13:561-571.
231. Shimozaki K, Nakajima K, Hirano T, Nagata S. 1997. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J Biol Chem 272:25184-25189. (Pubitemid 27415704)
232. Shuai K, Liu B. 2005. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 5:593-605. (Pubitemid 41113191)
233. Shuai K, Schindler C, Prezioso VR, Darnell JE, Jr. 1992. Activation of transcription by IFN-gamma: Tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258:1808-1812. (Pubitemid 23087351)
234. Shuai K, Stark GR, Kerr IM, Darnell JE, Jr. 1993. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 261:1744-1746. (Pubitemid 23332925)
235. Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D, Darnell JE, Jr. 1994. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76:821-828. (Pubitemid 24085320)
236. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ. 2002. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol 12:446-453. (Pubitemid 34248890)
237. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. 1999. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/- 5b-/- mice: A direct role for Stat5 in Bcl-X(L) induction. Cell 98:181-191.
238. Song L, Bhattacharya S, Yunus AA, Lima CD, Schindler C. 2006. Stat1 and SUMO modification. Blood 108:3237-3244.
239. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE, Jr, Yancopoulos GD. 1995. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349-1353.
240. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917-921. (Pubitemid 27289594)
241. Starr R, MetcalfD, Elefanty AG, Brysha M, Willson TA, Nicola NA, Hilton DJ, Alexander WS. 1998. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 95:14395-14399. (Pubitemid 28549378)
242. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S. 1996a. Impaired IL-13-mediated functions of macrophages in STAT6- deficient mice. J Immunol 157:3220-3222. (Pubitemid 126449129)
243. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T, Akira S. 1996b. Essential role of Stat6 in IL-4 signalling. Nature 380:627-630. (Pubitemid 26119015)
244. Takeda K, Noguchi K, ShiW, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S. 1997. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94:3801-3804. (Pubitemid 27180453)
245. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S. 1998. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 161:4652-4660. (Pubitemid 28492039)
246. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10:39-49. (Pubitemid 29077382)
247. Tanner JW, Chen W, Young RL, Longmore GD, Shaw AS. 1995. The conserved box 1 motif of cytokine receptors is required for association with JAK kinases. J Biol Chem 270:6523-6530.
248. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93:841-850. (Pubitemid 28257589)
249. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, Shuai K. 2002. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22:5662-5668. (Pubitemid 34815816)
250. Thiel S, Dahmen H, Martens A, Muller-Newen G, Schaper F, Heinrich PC, Graeve L. 1998. Constitutive internalization and association with adaptor protein-2 of the interleukin-6 signal transducer gp130. FEBS Lett 441:231-234. (Pubitemid 29027901)
251. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN. 1996. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171-174. (Pubitemid 26242884)
252. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. 1995. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270:794-797.
253. Tortolani PJ, Lal BK, Riva A, Johnston JA, Chen YQ, Reaman GH, Beckwith M, Longo D, Ortaldo JR, Bhatia K, McGrath I, Kehrl J, Tuscano J, McVicar DW, O'Shea JJ. 1995. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol 155:5220-5226.
254. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545-2552. (Pubitemid 28183424)
255. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. 1997. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 94:7239-7244. (Pubitemid 27345299)
256. Ungureanu D, Vanhatupa S, Kotaja N, Yang J, Aittomaki S, Janne OA, Palvimo JJ, Silvennoinen O. 2003. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 102:3311-3313. (Pubitemid 37314771)
257. Ungureanu D, Vanhatupa S, Gronholm J, Palvimo JJ, Silvennoinen O. 2005. SUMO-1 conjugation selectively modulates STAT1- mediated gene responses. Blood 106:224-226. (Pubitemid 40967196)
258. Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, Xu CF, Neubert TA, Skoda RC, Hubbard SR, Silvennoinen O. 2011. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 18:971-976.
259. Uotani S, Bjorbaek C, Tornoe J, Flier JS. 1999. Functional properties of leptin receptor isoforms: Internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 48:279-286. (Pubitemid 29061099)
260. Urban JF, Jr, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, Collins M, Finkelman FD. 1998. IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity 8:255-264. (Pubitemid 28123752)
261. van Kerkhof P, Strous GJ. 2001. The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand. Biochem Soc Trans 29:488-493. (Pubitemid 32783644)
262. Veals SA, Schindler C, Leonard D, Fu XY, Aebersold R, Darnell JE, Jr, Levy DE. 1992. Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol 12:3315-3324.
263. Velazquez L, Fellous M, Stark GR, Pellegrini S. 1992. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70:313-322.
264. Verbsky JW, Bach EA, Fang YF, Yang L, Randolph DA, Fields LE. 1996. Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells. J Biol Chem 271:13976-13980. (Pubitemid 26190287)
265. Verdier F, Chretien S, Muller O, Varlet P, Yoshimura A, Gisselbrecht S, Lacombe C, Mayeux P. 1998. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated C is protein. J Biol Chem 273:28185-28190. (Pubitemid 28496116)
266. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes- Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. 2010. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127.
267. Vinkemeier U, Cohen SL, Moarefi I, Chait BT, Kuriyan J, Darnell JE, Jr. 1996. DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: Interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. Embo J 15:5616-5626. (Pubitemid 26385621)
268. Visconti R, Gadina M, Chiariello M, Chen EH, Stancato LF, Gutkind JS, O'Shea JJ. 2000. Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood 96:1844-1852. (Pubitemid 30662111)
269. Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A. 1995. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. Embo J 14:2527-2535.
270. Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P. 2005. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 105:600-608. (Pubitemid 40070742)
271. Wang D, Stravopodis D, Teglund S, Kitazawa J, Ihle JN. 1996. Naturally occurring dominant negative variants of Stat5. Mol Cell Biol 16:6141-6148. (Pubitemid 26360974)
272. Wang Z, Li G, Tse W, Bunting KD. 2009. Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood 113:4856-4865.
273. Ward AC, van Aesch YM, Schelen AM, Touw IP. 1999. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood 93:447-458. (Pubitemid 29035726)
274. Watling D, Guschin D, Muller M, Silvennoinen O, Witthuhn BA, Quelle FW, Rogers NC, Schindler C, Stark GR, Ihle JN, et al. 1993. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 366:166-170.
275. Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, Kano A, Iwamoto Y, Li E, Craft JE, Bothwell AL, Fikrig E, Koni PA, Flavell RA, Fu XY. 2003. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity. Proc Natl Acad Sci USA 100:1879-1884. (Pubitemid 36254542)
276. Wilks AF. 1989. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA 86:1603-1607. (Pubitemid 19078951)
277. Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A. 1991. Two novel protein-tyrosine kinases, each with a second phosphotransferase- related catalytic domain, define a new class of protein kinase. Mol Cell Biol
278. Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, Fantino E, Rossjohn J, Lucet IS. 2009. Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 387:219-232.
279. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. 1993. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74:227-236. (Pubitemid 23221699)
280. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, Ihle JN. 1994. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370:153-157. (Pubitemid 24229129)
281. Wong KA, Kim R, Christofk H, Gao J, Lawson G, Wu H. 2004. Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life. Mol Cell Biol 24:5577-5586. (Pubitemid 38738187)
282. Wu TR, Hong YK, Wang XD, Ling MY, Dragoi AM, Chung AS, Campbell AG, Han ZY, Feng GS, Chin YE. 2002. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J Biol Chem 277:47572-47580. (Pubitemid 36159277)
283. Xu X, Sun YL, Hoey T. 1996. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 273:794-797. (Pubitemid 26271524)
284. Yamamoto K, Quelle FW, Thierfelder WE, Kreider BL, Gilbert DJ, Jenkins NA, Copeland NG, Silvennoinen O, Ihle JN. 1994. Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation. Mol Cell Biol 14:4342-4349. (Pubitemid 24196782)
285. Yamaoka K, Saharinen P, Pesu M, Holt VE, 3rd, Silvennoinen O, O'Shea JJ. 2004. The Janus kinases (Jaks). Genome Biol 5: 253.1-253.6.
286. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H. 1998. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 273: 30218-30224. (Pubitemid 28545486)
287. Yan H, Krishnan K, Greenlund AC, Gupta S, Lim JT, Schreiber RD, Schindler CW, Krolewski JJ. 1996. Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. Embo J 15:1064-1074.
288. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR. 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65:939-947. (Pubitemid 40216455)
289. Yao BB, Niu P, Surowy CS, Faltynek CR. 1999. Direct interaction of STAT4 with the IL-12 receptor. Arch Biochem Biophys 368:147-155. (Pubitemid 29372315)
290. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, Li D, Durum SK, Jiang Q, Bhandoola A, Hennighausen L, O'Shea JJ. 2006. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 103:1000-1005. (Pubitemid 43212211)
291. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo J 18:1309-1320. (Pubitemid 29110315)
292. Yeh TC, Dondi E, Uze G, Pellegrini S. 2000. A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc Natl Acad Sci USA 97:8991-8996. (Pubitemid 30626661)
293. Yen CH, Yang YC, Ruscetti SK, Kirken RA, Dai RM, Li CC. 2000. Involvement of the ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-type cytokine receptors of IL-9, IL-2, and erythropoietin. J Immunol 165:6372-6380.
294. Yoo JY, Huso DL, Nathans D, Desiderio S. 2002. Specific ablation of Stat3beta distorts the pattern of Stat3-responsive gene expression and impairs recovery from endotoxic shock. Cell 108:331-344. (Pubitemid 34178398)
295. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. 2001. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28:29-35. (Pubitemid 32405812)
296. You M, Yu DH, Feng GS. 1999. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/ STAT pathway. Mol Cell Biol 19:2416-2424. (Pubitemid 29098299)
297. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. 2005. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307:269-273. (Pubitemid 40116244)
298. Zeng R, Aoki Y, Yoshida M, Arai K, Watanabe S. 2002. Stat5B shuttles between cytoplasm and nucleus in a cytokine-dependent and -independent manner. J Immunol 168:4567-4575. (Pubitemid 34441362)
299. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE, Jr. 1996. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci USA 93:15092-15096. (Pubitemid 127606373)
300. Zhang Q, Ekhterae D, Kim KH. 1997. Molecular cloning and characterization of P113, a mouse SNF2/SWI2-related transcription factor. Gene 202:31-37. (Pubitemid 27523699)
301. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Kent SB, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, Baca M. 1999. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 96:2071-2076.
302. Zhang JG, Metcalf D, Rakar S, Asimakis M, Greenhalgh CJ, Willson TA, Starr R, Nicholson SE, Carter W, Alexander WS, Hilton DJ, Nicola NA. 2001. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci USA 98:13261-13265. (Pubitemid 33051350)
303. Zhang Z, Welte T, Troiano N, Maher SE, Fu XY, Bothwell AL. 2005. Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem Biophys Res Commun 328:800-807. (Pubitemid 40208320)
304. Zhao Y, Wagner F, Frank SJ, Kraft AS. 1995. The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta c chain. J Biol Chem 270:13814-13818.
305. Zhong Z, Wen Z, Darnell JE, Jr. 1994a. Stat3 and Stat4: Members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA 91:4806-4810. (Pubitemid 24177738)
306. Zhong Z, Wen Z, Darnell JE, Jr. 1994b. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95-98. (Pubitemid 24144493)
307. Zhong M, Henriksen MA, Takeuchi K, Schaefer O, Liu B, ten Hoeve J, Ren Z, Mao X, Chen X, Shuai K, Darnell JE, Jr. 2005. Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci USA 102:3966-3971. (Pubitemid 40388539)
308. Zhou YJ, Chen M, Cusack NA, Kimmel LH, Magnuson KS, Boyd JG, Lin W, Roberts JL, Lengi A, Buckley RH, Geahlen RL, Candotti F, Gadina M, Changelian PS, O'Shea JJ. 2001. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: Structural implication for Janus kinases. Mol Cell 8:959-969. (Pubitemid 34031799)
309. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8:967-974. (Pubitemid 47300011)